Dallas, Texas 02/25/2014 (FINANCIALSTRENDS) – Delcath Systems, Inc.(NASDAQ:DCTH) is a leading pharmaceutical which also offers a variety of medical equipment. The company also offers development stage special purpose drugs which are essential in treating cancers.
The specialty of this drug maker is in treating cancer of the liver.
Delcath Systems, Inc.(NASDAQ:DCTH) has brought forth its solution sets based on the chemosaturation system. Here the technology is about administering the solution with the regional chemostherapy through a process called as isolation of circulatory system. The target organ is the isolated and the solution ensures delivery of does through the agents which are chemotherapeutic agents to the liver itself.
Currently, the Delcath Systems, Inc.(NASDAQ:DCTH) is also involved in a series of solutions which are delivered through three insertions. These insertions are placed in the catheter nad are placed near the percutaneous as well as interventional radiology techniques.
Delcath Systems, Inc.(NASDAQ:DCTH) also offers solutions whereby the invasive operations required are minimized. The repeatable as well as the multiple courses of treatment which the drug will support are largely in the chemical therapy region. It has to be noted that this company has also offered one of the latest standards of approval by the European standards. The Delcath Hepatic Cheosat Delivery system is one such solution.
Financial overview
Delcath Systems, Inc.(NASDAQ:DCTH) currently hold market cap of $40.30 million. The average volume is in the range of $2.46 million to $5.585 million. The overall range of this stock is $0.30 to 0.32. The 52-week coverage for this stock has thus far been $0.22 to $2.19. EPS is -0.40 and Beta is 2.36.
Delcath Systems, Inc.(NASDAQ:DCTH) is headquartered in New York and is known advocate of cancer solutions and causes. The advantage with therapy solutions which this company provides is invasive solution which also allows multiple course treatment of drugs to fight cancer.